LY-CoV1404 entered the Phase II BLAZE-4 trial (NCT04634409), which was expanded to study the antibody’s safety and effectiveness in patients with mild-to-moderate COVID-19, alone and in several combinations—including one with bamlanivimab, and one with another antibody that Lilly is developing with Shanghai Junshi Biosciences, etesevimab (LY-CoV016 or JS-16 . . .
See More on the Edge
Continue reading this article and more
with a GEN Edge subscription
The post AbCellera, Lilly Advance Next-Generation Antibody vs. COVID-19 appeared first on GEN – Genetic Engineering and Biotechnology News.
